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Abstract
Background: Cardiac hypertrophy is a major risk factor for morbidity and mortality in a number
of cardiovascular diseases. Consequently, the signaling pathways that inhibit cardiac hypertrophy
are currently receiving much interest. Among them, nitric oxide (NO), signaling via cGMP and
cGMP-dependent protein kinase I, has been recognized as a negative regulator of cardiac
hypertrophy. The present study investigated the in-vivo effect of sildenafil as a phosphodiestrase-
5A (PDE-5A) inhibitor on the hypertrophic response of rat heart to isoproterenol and the relation
of this effect to the level of myocardial cGMP and integrity of the constitutive nitric oxide synthase
(cNOS) activity.
Results: The results showed that daily intraperitoneal administration of sildenafil per se for 10 days
was without noticeable adverse effects on survival or myocardium. Conversely, daily subcutaneous
administration of isoproterenol for 10 days caused significant myocardial hypertrophy, cell injury
and decline in survival. When sildenafil was injected daily, one hour before isoproterenol, survival
was significantly improved and the myocardium didn't show significant hypertrophy or cell injury.
Interestingly, sildenafil was accompanied by significant rise in myocardial cGMP level, a parameter
which was found in the present study to possess a significant negative correlation with cardiac
hypertrophy and leak of cardiac troponin T into serum. At the same time, cGMP was found to
possess a positive correlation with myocardial creatine kinase activity that reflects the efficiency of
the energy utilization processes in the myocardium. However, in rats given Nω -nitro-L-arginine (L-
NNA) as a competitive inhibitor of cNOS, sildenafil failed to show any favorable effect on survival
or the myocardial injury parameters used to assess isoproterenol-induced injury.
Conclusion: The present study suggests that increased cardiac cGMP level by sildenafil have a
cardioprotective effect probably through acting as a post-receptor negative regulator of cardiac
sympathetic responsiveness. Integrity of NOS function was an essential prerequisite for sildenafil's
mediated cardioprotection encountered in the present study.
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Background
Sildenafil is a selective inhibitor of phosphodiesterase-5A
(PDE-5A), the enzyme that hydrolyzes cGMP. Sildenafil is
orally effective in the treatment of erectile dysfunction. Its
pharmacological action is due to prolonging the signaling
actions of nitric oxide (NO) in penile smooth muscle [1].
Interestingly, a recent publication reported a pronounced
infarct size-reducing effect of sildenafil in an in-vivo rab-
bit model of coronary occlusion [2]. Reduced infarct size
by sildenafil has also been reported in mice and rat heart
subjected to global ischemic/reperfusion (I/R) injury
[3,4]. In those studies, opening of mitochondrial ATP-
sensitive K channels, induction of NO synthase (NOS)
isoforms and increased cGMP level by sildenafil were sug-
gested to mediate a preconditioning-like cardioprotective
effect [2-4].
As regards myocardial hypertrophy, a great number of in-
vivo and in-vitro studies tested the role of many signaling
pathways involved in its induction [5]. At the same time,
the role of the negative regulators such as NO, atrial natri-
uretic peptide and cGMP have so far received much less
attention until recently recognized to be of particular sig-
nificance [6,7]. Alternatively, drugs that modulate the
NO-cGMP signaling pathway like sildenafil and probably
its congeners may be useful especially that sildenafil
proved to be cardioprotective in models of cardiac I/R
injury.
To address this issue, the present study examined the car-
dioprotective effect of sildenafil in a rat model of ventricu-
lar hypertrophy and myocardial cell injury induced by the
β -adrenergic agonist isoproterenol. The model is charac-
terized by technical simplicity, excellent reproducibility
and an acceptable level of mortality [8]. Previous studies
in rats revealed that isoproterenol induced a dose-depend-
ent increase in ventricular end diastolic pressure and glo-
bal wall stress that were associated with compensatory
hypertrophy and repair fibrosis [5,9]. However, in the
present study, the following parameters were assessed:
rate of survival among experimental groups, heart coeffi-
cient, myocardial cGMP level, myocardial creatine kinase
activity and serum level of cardiac troponin T (cTnT). In
addition, the role of constitutive NOS was examined by
adding the NOS inhibitor Nω -nitro-L-arginine (L-NNA) to
drinking water of a group of sildenafil and isoproternol
treated rats.
Results
Cumulative survival curves (Fig. 1)
In group I (vehicle control) and group IV (sildenafil/vehi-
cle), survival was 100 % till termination of study (10
days). In group II (isoproterenol) and group V (sildenafil/
isoproternol/L-NNA), survival was 53.33% (8/15) in each
group. In group III (sildenafil/isoproternol) survival was
86.67% (13/15). By log-rank test, significant improve-
ment in survival rate was found in group III compared to
groups II and V (P < 0.05).
Heart coefficient, myocardial creatine kinase (CK) 
activity, myocardial cGMP level and serum cardiac 
troponin T (cTnT)
Table I shows significant increase in heart coefficient in
group II (isoproterenol) and group V (sildenafil/isoprot-
erenol/L-NNA) compared to group I (vehicle control),
group III (sildenafil/isoproternol) and group IV (sildena-
fil/vehicle) denoting occurrence of cardiac hypertrophy in
the former groups. Also, significant myocardial cell injury
in group II and group V was indicated by the decline of
myocardial CK activity and leak of cTnT into serum in
these groups compared to group I. At the same time, myo-
cardial CK activity and serum level of cTnT in group III
and group IV were normal and comparable to group I
Kaplan-Meier analysis of 10 days survival among 70 rats clas- sified into vehicle (group I, n= 10; solid line), isoproterenol  (group II, n = 15; thick dotted intermediate curve), isoproter- enol/ sildenafil (group III, n = 15; thick dashed curve), sildena- fil/vehicle(group IV, n = 15; solid line) and sildenafil/ isoproternol/ Nω -nitro-L-arginine (group V, n = 15; thin  dash-dot line to the left) Figure 1
Kaplan-Meier analysis of 10 days survival among 70 rats clas-
sified into vehicle (group I, n= 10; solid line), isoproterenol 
(group II, n = 15; thick dotted intermediate curve), isoproter-
enol/ sildenafil (group III, n = 15; thick dashed curve), sildena-
fil/vehicle(group IV, n = 15; solid line) and sildenafil/
isoproternol/ Nω -nitro-L-arginine (group V, n = 15; thin 
dash-dot line to the left). Significant improvement in survival 
rate was found by log-rank test in group III compared to 
groups II and V (P < 0.05).BMC Pharmacology 2005, 5:10 http://www.biomedcentral.com/1471-2210/5/10
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(homogenous subset). Elevated myocardial cGMP was
found in two sildenafil groups (III and IV) compared to
other groups (I, II and V).
Correlation of myocardial cGMP level to other parameters
The linear regression curves shown in the figures 2, 3, 4,
demonstrate significant correlations between myocardial
cGMP level and heart coefficient (r = - 0.65, P < 0.001),
myocardial CK activity (r = 0.59, P < 0.001) and serum
cTnT level (r = - 0.43, P < 0.01). Individual data from all
studied rats were included in the correlation analysis.
Discussion
Dealing with cardiac hypertrophy is currently a major goal
of cardiovascular research and clinical trials[5]. The cardi-
omyocytes undergo hypertrophy in some pathological
conditions that impose overwork on the heart e.g. hyper-
tension, heart valve diseases, myocardial infarction, and
Table 1: The heart coefficient (mg/g body wt.), myocardial cGMP level (pmoles/g wet tissue), CK activity (U/mg tissue protein) and 
serum level of cTnT (ng/ml) in rats after 10 days of treatment with: vehicle (group I), isoproterenol (group II), sildenafil/ isoproterenol 
(group III), sildenafil (group IV) and sildenafil/isoproternol/ Nω -nitro-L-arginine (group V).
Heart coefficient Myocardial cGMP Myocardial CK Serum cTnT
Group I n = 10 3.33 ± 0.18* 4.76 ± 1.03** 6.03 ± 0.35** 0.38 ± 0.13*
Group II n = 8 5.27 ± 0.17** 4.12 ± 1.36** 3.10 ± 0.35* 6.50 ± 1.29***
Group III n = 13 3.75 ± 0.48* 10.51 ± 3.05*** 5.62 ± 0.44** 3.71 ± 1.16**
Group IV n = 15 3.49 ± 0.67* 10.14 ± 3.24*** 5.80 ± 1.02** 0.75 ± 0.28*
Group V n = 8 5.31 ± 0.47** 1.80 ± 0.54* 3.47 ± 0.37* 6.34 ± 1.14***
NB: Isoproterenol was given at the dose of 5 mg/kg daily s.c. and sildenafil was given at the dose of 0.7 mg/kg daily i.p. and Nω -nitro-L-arginine was 
added to drinking water at the concentration of 10 mg/L.
Values are mean ± SEM. n: number of rats survived for 10 days
One-way ANOVA test followed by Student-Newman-Keuls post-hoc test. Values forming homogeneous subsets are as follow: *homogeneous 
subset 1, ** homogeneous subset 2 and *** homogeneous subset 3. Significant difference existed between different subsets (P < 0.05)
Linear regression curve for myocardial cGMP level and heart  coefficient Figure 2
Linear regression curve for myocardial cGMP level and heart 
coefficient.
Linear regression curve for myocardial cGMP and myocardial  creatine kinase (CK) activity Figure 3
Linear regression curve for myocardial cGMP and myocardial 
creatine kinase (CK) activity.BMC Pharmacology 2005, 5:10 http://www.biomedcentral.com/1471-2210/5/10
Page 4 of 7
(page number not for citation purposes)
cardiomyopathy [16]. Such cardiac hypertrophy is ini-
tially compensatory for an increased work load, however,
prolongation of this process eventually leads to congestive
heart failure, arrhythmia, and sudden death [16]. Todate,
drugs targeting the renin-angiotensin system are the chief
class of cardiovascular agents of special clinical utility in
settings predisposing to cardiac hypertrophy based on the
important role of angiotensin II in growth of cardiomyo-
cytes [17].
In an attempt to examine other signaling pathways and
other drugs, the present study probed the NO-cGMP path-
way and the effect of its modulation by the selective PDE-
5A inhibitor sildenafil in cardiac hypertrophy. The β -
adrenergic agonist isoproterenol was subcutaneously
injected in rats for 10 days to induce cardiac hypertrophy.
Obtained results showed that sildenafil administration
one hour before daily s.c. injection of isoproterenol was
associated with significant improvement in survival and
significant inhibition of cardiac hypertrophy. Also, the
myocardium of the sildenafil-isoproterenol treated rats
showed higher activity of myocardial CK activity and less
cTnT leaked into the blood compared to isoproterenol-
treated rats. These findings suggest that sildenafil con-
ferred a significant anti-hypertrophic and cytoprotective
effect on cardiomyocytes. Conversely, the decline in myo-
cardial CK activity and increased leak of cTnT into serum
observed in the isoproterenol treated rats and in rats sub-
jected to NOS inhibition denote significant impairment
in tissue energy metabolism and loss of cell integrity,
respectively. In the myocardium, ATP is synthesized
mainly in the mitochondria through oxidative
phosphorylation and transported to the contractile appa-
ratus, where it is consumed by myosin ATPase to generate
force. The creatine kinase system plays an important role
in myocardial energy metabolism by maintaining ADP
levels high at the mitochondria, where ATP is generated,
and low at sites of ATP utilization [18]. This is postulated
to contribute to the maintenance of a high free energy of
ATP hydrolysis, thereby enhancing the efficiency of the
energy utilization processes [18]. In addition, a CK shuttle
has been proposed, in which high-energy phosphate
transport within the cell is facilitated by the higher diffus-
ibility of creatine and phosphocreatine relative to ADP
[18].
As regards cardiac troponins T, I and C, they regulate mus-
cle contraction by modulating calcium-dependent inter-
action of actin and myosin. These intracellular structural
proteins are released into circulation following loss of cell
integrity [19].
An interesting observation in the present study was that,
in the presence of the cNOS inhibitor L-NNA, sildenafil
was deprived from its antihypertrophic and cytoprotective
effects in isoproterenol-treated rats. Also, the significant
correlations found between tissue cGMP level on one
hand and heart coefficient, myocardial CK activity and
serum level of cTnT on the other hand, suggest that the
integrity of the NO-cGMP signaling pathway plays a piv-
otal role in the cardioprotective effect of sildenafil.
The second messenger cGMP that was identified almost
40 years ago, is generated from GTP either by soluble gua-
nyl cyclase or particulate guanyl cyclase [20]. The former
is activated by nitric oxide (NO) or carbon monoxide,
where as the latter binds a family of natriuretic peptides
consisting of atrial, brain, and C-type natriuretic peptides
[20]. On the other hand, various phosphodiesterases reg-
ulate cGMP catabolism, including PDE-5A, PDE-6, PDE-
9A, PDE-10A, and PDE-11A according to their tissue spe-
cificity [21-23]. Among these, PDE-5A is the most widely
studied, and its inhibition is a primary mechanism for
efficacy of sildenafil in erectile dysfunction [1]. Previous
studies have shown that inhibition of PDE-5A in the myo-
cardium enhanced coronary blood flow during exercise-
induced ischemia, blunted cardiac stimulation by dob-
utamine and reduced contractility of adrenergically stim-
ulated papillary muscle [22-24]. In accordance with this,
inhibition of PDE-5A in rat myocardium probably under-
lies the cardioprotective effect of sildenafil against isopro-
terenol-induced cardiac hypertrophy observed in the
Linear regression curve for myocardial cGMP and serum  level of cardiac troponin T (cTnT) Figure 4
Linear regression curve for myocardial cGMP and serum 
level of cardiac troponin T (cTnT).BMC Pharmacology 2005, 5:10 http://www.biomedcentral.com/1471-2210/5/10
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present study. At cellular level, the common denominator
in all these studies is probably the increased cellular level
of cGMP.
In non stimulated hearts, cGMP has been suggested to
augment contractile function at low concentrations, likely
via cross-talk with cAMP-dependent signaling, inhibiting
PDE-3 and degradation of cAMP [25]. At higher concen-
trations, cGMP has a negative inotropic effect by
antagonizing cAMP via protein kinase G (in mammals) or
PDE-2 stimulation (in amphibians) [25]. With β -adrener-
gic activation, both cAMP and cGMP synthesis increase,
with the net effect of cGMP being negative on the ino-
tropic response (a brake) [26]. Conversely, reducing
cGMP level e.g. by NOS inhibition, enhances β -adrenergic
responsiveness [27]. In addition to the negative inotropic
action of cGMP, it reduces oxygen consumption and off-
sets the development of cardiac hypertrophy [28,29].
Consequently, PDE-5A inhibition by sildenafil and cellu-
lar accumulation of cGMP would be the braking force
against isoproterenol-induced cardiac hypertrophy found
in the present study. Consistent with this assumption,
over-expression of the catalytic fragment of the
constitutively active guanylate cyclase domain of the atrial
natriuretic peptide receptor in mouse heart increased the
intracellular concentration of cGMP within cardiomyo-
cytes and attenuated the effects of isoproterenol on car-
diac wall thickness and prevented fetal gene expression
program normally associated with cardiac hypertrophy
[30]. Conversely, disruption of cardiac guanylate cyclase-
A (GC-A) gene resulted in mice that displayed elevation of
blood pressure, cardiac fibrosis and hypertrophy [31].
Conclusion
The present study suggests that sildenafil possesses a car-
dioprotective and antihypertrophic effect against isoprot-
erenol-induced myocardial injury. Inhibition of cGMP
degradation by sildenafil with a consequent accumulation
of this signaling molecule may act as a negative regulator
against cardiac hypertrophy in-vivo. Understanding the
downstream molecular mechanism(s) of such effect of
sildenafil, may expand the utility of this drug beyond the
current use for treatment of erectile dysfunction in men.
The study also revealed that integrity of function of cNOS
is an essential prerequisite for the cardioprotective effect
of sildenafil in the adrenergically stimulated heart.
Methods
Experimental animals
The present study was conducted on 70 male albino rats
of 5 months age, weighing 200–230 g/rat, from those
bred in the animal house of the Pharmacology Depart-
ment, Faculty of Medicine, Alexandria University, Egypt.
Rats were kept in galvanized iron cages in groups of 2–3
rats/cage, at room temperature of 22–25°C and allowed
free access to standard chow diet and tap water. The study
was carried out in accordance with the local guidelines for
animal experimentation.
Drugs, chemicals and kits
Isoproterenol and chemicals were purchased from Sigma-
Aldrich, Inc. (USA). Sildenafil tablets of Pfizer Inc. (Viagra
100 mg/tablet) were crushed and dissolved in saline for
intraperitoneal injection. Direct cGMP enzyme immu-
noassay kit (CG-200, Sigma-Aldrich, Inc. USA) was used
to measure myocardial cGMP level. Cardiac troponin T
enzyme immunoassay kit (ES300, Boehringer Mannheim
Immunodiagnostics, Germany) was used to measure
serum cTnT.
Nω -nitro-L-arginine (L-NNA) was purchased from Cay-
man chemical, USA.
Experimental groups and treatment
Rats were randomly assigned into 5 groups:
Group I (n = 10): A control group that received vehicle
(saline) instead of drug injection.
Group II (n = 15): Isoproterenol was injected s.c. at a dose
of 5 mg/kg/day [10].
Group III (n = 15): Sildenafil was injected i.p. at a dose of
0.7 mg/kg/day, one hour prior to isoproterenol. The drug
was given in an experimental dose approximating, on a
mg/kg basis, the clinical dose of 50 mg administered to a
70-kg patient as described by Okcaili et al [2].
Group IV (n = 15): Sildenafil was injected i.p. at men-
tioned dose, one hour prior to s.c. injection of saline
instead of isoproterenol. This group served as a control for
Group III.
Group V (n = 15): Drugs given to this group were essen-
tially similar to group III, however, the NOS inhibitor Nω -
nitro-L-arginine (L-NNA) was added to drinking water of
this group at the concentration of 10 mg/L. This
concentration was selected on the previously reported
insignificant effect on blood pressure in rats [11].
Determination of survival, serum level of cTnT and heart 
coefficient
The study continued for 10 days [10]. The number of sur-
vivors in each group was recorded daily and on day 11th,
3 ml-trunkal blood sample/rat was collected under light
ether anesthesia from the inferior vena cava and centri-
fuged for 15 min at 3000 r.p.m. Sera were kept frozen at -
20°C until assayed for cardiac troponin T according to
general principles of ELISA technique [12] and theBMC Pharmacology 2005, 5:10 http://www.biomedcentral.com/1471-2210/5/10
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manufacturer's instructions (Boehringer- Mannheim
Immunodiagnostics, Germany), with a lower limit of
detection of 0.01 ng/ml. The means ± SEM were deter-
mined for triplicate samples.
From each rat, the heart was excised immediately after rat
sacrifice and weighed to calculate the ratio of heart weight
to body weight (heart coefficient) [10].
Determination of myocardial creatine kinase (CK) activity
Tissue extract of apical myocardium was prepared by
homogenization in cold 20 mM Tris/HCl buffer at the
ratio of 1:3 (w/v), pH 7.5, containing 1 mM EDTA and 1
mM β -mercaptoethanol. Cellular debris were removed by
centrifugation at 4°C for 60 minutes at 15.000 r.p.m. and
the supernatant was used for the assay of CK activity spec-
trophotometrically at 340 nm, as recommended by the
International Federation of Clinical Chemistry [13]. Crea-
tine kinase is primarily concerned with ATP regeneration
through catalyzing the following reaction:
Adenosine diphosphate (ADP) + phosphocreatine 
ATP + Creatine.
The present assay of CK activity was based on the forma-
tion of ATP linked to the production of NADHP via hex-
okinase and glucose-6-phosphate dehydrogenase. The
reaction mixture contained 100 mM imidazole acetate, 2
mM EDTA, 10 mM magnesium acetate, 2 mM ADP, 5 mM
AMP, 20 mM D-glucose, 2 mM NADP, 30 mM phospho-
creatine, hexokinase (3 U/ml), and glucose-6-phosphate
dehydrogenase (2 U/ml), pH 6.7. One unit CK activity is
that converts one micromole of creatine phosphate to cre-
atine per minute at the given pH.
The protein concentration in supernatant tissue extract
was determined by Lowry method [14].
Determination of myocardial cGMP level
Frozen myocardial tissue samples in liquid nitrogen were
ground to a fine powder in a stainless steel mortar. After
the liquid nitrogen was evaporated, the frozen tissue was
weighed and homogenize in 10 volumes of 0.1 M HCl to
stop the action of phosphodiesterases. Centrifugation was
done at 30.000 r.p.m. at room temperature and the super-
natant was then collected for quantitative immunoassay
of cGMP level according to general principle of ELISA
technique [12] and the manufacturer's instructions (CG-
200, Sigma-Aldrich, Inc. USA). The assay used a polyclo-
nal antibody to cGMP to bind, in a competitive manner,
cGMP in samples and standards or cGMP covalently
attached to alkaline phosphatase. After incubation with
the p-nitrophenyl phosphate substrate, a microplate
autoreader (Bio-Tek Instruments EL311) was used to
measure the intensity of the bound yellow colour at 405
nm. The measured optical density was used to calculate
the concentration of cGMP in samples by interpolation
from Logit-Log paper plot of the percent bound (B/Bo)
versus concentration of cGMP for the standards.
Statistical analysis
Data were analyzed by SPSS/PC, version 9 Chicago/L soft-
ware. The survival curves were generated using the
method of Kaplan and Meier, and the log-rank test was
used to detect significant difference between survival
curves. Values of other parameters were expressed as mean
± SEM (standard error of mean). Other parameters were
compared by one-way ANOVA, with post-hoc compari-
sons by Student Newman-Keuls test. Correlation studies
were carried out by linear regression with curve
estimation. For all of the determinations, P < 0.05 was
used to indicate statistical significance [15].
Abbreviations
ADP, adenosine diphosphate; ATP, adenosine triphos-
phate; cAMP, cyclic adenosine monophosphate; cGMP:
cyclic guanosine monophosphate; CK, creatine kinase;
cTnT: cardiac troponin T; GC, guanyl cyclase; s.c., subcute-
anous; i.p., intraperitoneal; NO, nitric oxide; cNOS,
constitutive nitric oxide synthase; PDE, phosphodieste-
rase; w/v, weight/volume.
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